secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rain Oncology Inc. (—)
CIK:        0001724979
Form:       8-K
Filed at:   2023-06-05T23:59:59+00:00
Accession:  0001193125-23-160744
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 5.02, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rain Oncology cuts 65% workforce, suspends Phase 2/1 trials, extends cash runway
--------------------------------------------------------------------------------

- Restructuring plan cuts ~65% of employees; expects $2.4M-$2.6M in charges in Q2 2023.
- Suspends enrollment in Phase 2 MANTRA-2 basket trial; terminates plans for Phase 1/2 MANTRA-4 combo trial.
- Richard Bryce transitions from CMO to advisory role; Robert Doebele named CMO. Joy Bruce becomes principal financial officer.
- Year-end 2023 cash guidance $75-$80M; cash runway extended to year-end 2026.
- Phase 3 MANTRA milademetan data to be presented at a medical conference in 4Q 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724979/000119312523160744/0001193125-23-160744-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724979/000119312523160744/d441631d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-160744

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer